EMA Authorised: Kimmtrak (tebentafusp) — Immunocore Ireland Limited

View source ↗

Summary

EMA authorised Kimmtrak (tebentafusp) from Immunocore Ireland Limited for uveal melanoma, signaling EU approval of this first-in-class therapy for this eye canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• KIMMTRAK (tebentafusp)

Snippet

Status: Authorised. Therapeutic area: Uveal Neoplasms. MAH: Immunocore Ireland Limited. Decision date: 08/12/2025. Orphan medicine